KR102932817B1 - 인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체 - Google Patents

인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체

Info

Publication number
KR102932817B1
KR102932817B1 KR1020227001501A KR20227001501A KR102932817B1 KR 102932817 B1 KR102932817 B1 KR 102932817B1 KR 1020227001501 A KR1020227001501 A KR 1020227001501A KR 20227001501 A KR20227001501 A KR 20227001501A KR 102932817 B1 KR102932817 B1 KR 102932817B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
mmol
stirred
reaction
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227001501A
Other languages
English (en)
Korean (ko)
Other versions
KR20220024608A (ko
Inventor
에릭 피 길리스
크리스티아나 이와그우
Original Assignee
비브 헬스케어 유케이 (넘버5) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비브 헬스케어 유케이 (넘버5) 리미티드 filed Critical 비브 헬스케어 유케이 (넘버5) 리미티드
Publication of KR20220024608A publication Critical patent/KR20220024608A/ko
Application granted granted Critical
Publication of KR102932817B1 publication Critical patent/KR102932817B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227001501A 2019-06-19 2020-06-17 인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체 Active KR102932817B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
US62/863,406 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (en) 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
KR20220024608A KR20220024608A (ko) 2022-03-03
KR102932817B1 true KR102932817B1 (ko) 2026-03-04

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227001501A Active KR102932817B1 (ko) 2019-06-19 2020-06-17 인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체

Country Status (33)

Country Link
US (2) US12129255B2 (https=)
EP (1) EP3986561B1 (https=)
JP (1) JP7628512B2 (https=)
KR (1) KR102932817B1 (https=)
CN (2) CN119039288A (https=)
AR (1) AR119174A1 (https=)
AU (1) AU2020295793B2 (https=)
BR (1) BR112021025655A2 (https=)
CL (1) CL2021003388A1 (https=)
CO (1) CO2021017479A2 (https=)
CR (1) CR20210664A (https=)
DK (1) DK3986561T3 (https=)
ES (1) ES2974541T3 (https=)
FI (1) FI3986561T3 (https=)
HR (1) HRP20240501T1 (https=)
HU (1) HUE065762T2 (https=)
IL (1) IL288750B2 (https=)
LT (1) LT3986561T (https=)
MA (1) MA56526B1 (https=)
MD (1) MD3986561T2 (https=)
MX (1) MX2021016149A (https=)
MY (1) MY206712A (https=)
PE (1) PE20220510A1 (https=)
PH (1) PH12021553180A1 (https=)
PL (1) PL3986561T3 (https=)
PT (1) PT3986561T (https=)
RS (1) RS65304B1 (https=)
SI (1) SI3986561T1 (https=)
SM (1) SMT202400153T1 (https=)
TW (1) TWI850403B (https=)
UA (1) UA128967C2 (https=)
UY (1) UY38755A (https=)
WO (1) WO2020254985A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004593A (es) 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
LT3986561T (lt) 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai
WO2020254559A1 (en) 2019-06-19 2020-12-24 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US20220347174A1 (en) * 2019-10-01 2022-11-03 Viiv Healthcare Company Method for treating HIV with Cabotegravir and Rilpivirine
UY38982A (es) * 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
CN115397424A (zh) * 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
US20240423985A1 (en) * 2021-10-13 2024-12-26 Viiv Healthcare Uk (No.5) Limit-Ed Inhibitors of human immunodeficiency virus replication
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203235A1 (en) 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
IL157029A0 (en) 2001-02-02 2004-02-08 Bristol Myers Squibb Co Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same
CN102143962B (zh) * 2008-07-02 2015-03-11 爱维艾珂瑟有限公司 具有抗病毒特性的化合物
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
CA2896244C (en) 2013-01-09 2017-07-04 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
KR20230011471A (ko) 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
EP3507288B1 (en) * 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
MX2021004593A (es) * 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
LT3986561T (lt) 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203235A1 (en) 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
EP3986561B1 (en) 2024-02-14
JP2022537047A (ja) 2022-08-23
SI3986561T1 (sl) 2024-04-30
MA56526A (fr) 2022-04-27
BR112021025655A2 (pt) 2022-02-01
FI3986561T3 (fi) 2024-05-02
MY206712A (en) 2025-01-03
CN119039288A (zh) 2024-11-29
KR20220024608A (ko) 2022-03-03
IL288750B2 (en) 2025-04-01
UY38755A (es) 2020-11-30
SMT202400153T1 (it) 2024-05-14
AU2020295793B2 (en) 2023-07-06
PL3986561T3 (pl) 2024-06-10
EP3986561A1 (en) 2022-04-27
AU2020295793A1 (en) 2022-01-20
PH12021553180A1 (en) 2022-11-07
CR20210664A (es) 2022-01-21
HRP20240501T1 (hr) 2024-07-05
DK3986561T3 (da) 2024-03-04
TW202115055A (zh) 2021-04-16
MD3986561T2 (ro) 2024-06-30
MX2021016149A (es) 2022-05-18
UA128967C2 (uk) 2024-12-11
AR119174A1 (es) 2021-12-01
CO2021017479A2 (es) 2022-04-19
WO2020254985A1 (en) 2020-12-24
IL288750B1 (en) 2024-12-01
US12129255B2 (en) 2024-10-29
CL2021003388A1 (es) 2022-09-30
HUE065762T2 (hu) 2024-06-28
IL288750A (en) 2022-02-01
CN114245795B (zh) 2024-08-06
RS65304B1 (sr) 2024-04-30
JP7628512B2 (ja) 2025-02-10
MA56526B1 (fr) 2024-05-31
CN114245795A (zh) 2022-03-25
LT3986561T (lt) 2024-04-25
PT3986561T (pt) 2024-03-15
US20250019383A1 (en) 2025-01-16
PE20220510A1 (es) 2022-04-07
CA3143136A1 (en) 2020-12-24
TWI850403B (zh) 2024-08-01
US20210323967A1 (en) 2021-10-21
ES2974541T3 (es) 2024-06-27

Similar Documents

Publication Publication Date Title
KR102932817B1 (ko) 인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체
EP3917930B1 (en) Inhibitors of human immunodeficiency virus replication
JP7799620B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7545414B2 (ja) ヒト免疫不全ウイルス複製阻害剤
US20230106880A1 (en) Inhibitors of human immunodeficiency virus replication
RU2804033C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
CA3143136C (en) Pyrido[2,3-d]pyrimidine derivatives as capsid inhibitors for treating human immunodeficiency virus
HK40066649B (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
HK40066649A (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
EA044806B1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BR122024007306A2 (pt) Composição farmacêutica que compreende o composto da fórmula ia, fórmula ib, fórmula ic ou fórmula id e uso da mesma para tratamento de infecção por hiv

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)